首页 > 市场调查报告书 > 製药

临床实验

市场调查报告书

商品编码

1874007

慢性咳嗽市场

Chronic Cough Market

出版日期: 2025年11月01日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

2024年，慢性咳嗽市场价值约为91.5亿美元，预计到2031年将成长至136亿美元。该市场预计在2031年至2032年间将维持8.2%的年复合成长率（CAGR）。人们对呼吸系统疾病的认识不断提高、医学研究和治疗方案的进步，以及持续的药物研发趋势，预计将成为影响慢性咳嗽市场的重要因素。

慢性咳嗽市场分析

全球慢性咳嗽市场主要由慢性肺部感染发病率上升以及新型慢性咳嗽疗法的推出所推动，因为持续咳嗽是慢性肺部感染的常见症状。此外，人们日益重视呼吸系统健康，以及政府和非政府组织的相关倡议，也促进了市场成长。

慢性咳嗽市场概览

慢性咳嗽是指持续八週或更长的咳嗽。它可能由感染、气喘和胃食道逆流（GERD）引起。慢性咳嗽的相关症状包括鼻后滴漏（黏液反流感）、头痛、频繁清嗓、咽喉痛、声音沙哑、呼吸急促、喘息、口中发酸和烧心。近年来，医疗基础设施、诊断服务和病患教育计画的投入显着增加，旨在加强慢性咳嗽的管理和早期发现。

战略洞察

慢性咳嗽市场驱动因素与机会

慢性咳嗽发生率上升将推动市场成长

感染、肺部疾病和支气管炎等疾病可能是导致慢性咳嗽的因素。全球气喘病例的增加，尤其是在儿童和成人中，是一个值得关注的现象。一项题为「慢性咳嗽的盛行率、其危险因子和人群归因风险：一项多国横断面研究」（发表于2024年2月）的研究报告称，慢性咳嗽的盛行率在2%至18%之间。常见的慢性咳嗽相关因素包括吸烟、气喘、慢性阻塞性肺病（COPD）、肥胖、上呼吸道咳嗽症候群（UACS）和胃食道逆流（GERD）。

预计老年人口增长将增加对慢性咳嗽治疗的需求

老年人更容易患慢性咳嗽，老化是免疫力下降的主要因素。随着年龄增长，器官和健康组织会退化，引发各种健康问题，慢性咳嗽在老年族群中尤其常见。随着年龄增长，呼吸系统功能逐渐衰退，增加肺炎、流感等呼吸道感染的风险。

全球人口老化日益加剧，已开发国家和发展中国家的死亡率均下降。医疗保健水准的提高改善了公众健康，从而延长了预期寿命。世界卫生组织（世卫组织）预测，到2050年，全球60岁及以上人口预计将达到21亿，其中80岁及以上人口数量预计将在2020年至2050年间增长两倍，达到4.26亿。因此，不断增长的老龄人口很可能在预测期内推动对慢性咳嗽治疗的需求。

慢性咳嗽市场报告細項分析

慢性咳嗽市场分析按药物类别、给药途径和配销通路进行细分。

依药物类别划分，市场包括抗组织胺、皮质类固醇、减充血剂、复方製剂、抗生素、抑酸剂及其他类别。 2023年，复方製剂占据了最大的市场份额。
依给药途径划分，市场可分为口服、注射、吸入和其他途径。 2023年，口服途径占最大的市占率。
就分销管道而言，市场分为医院药房、线上药房和零售药房，其中医院药房在 2023 年将引领市场。

按地域分類的慢性咳嗽市场份额分析

慢性咳嗽市场报告的地理分析分为五个地区：北美、亚太、欧洲、中东和非洲以及南美和中美洲。

北美一直是慢性咳嗽市场的主导地区。预计在预测期内，非处方药（OTC）需求的成长将是推动该地区收入成长的重要因素。此外，慢性咳嗽病例的增加、老年人口的快速增长、车辆污染的加剧以及人们对先进治疗方案的认识不断提高，都促进了对止咳药的需求。

慢性咳嗽市场报告范围

慢性咳嗽市场新闻及最新动态

慢性咳嗽市场评估是基于从一手和二手研究中获得的定性和定量资料，包括主要企业出版物、协会资料和资料库。慢性咳嗽市场的最新发展包括：

临床阶段生物製药公司Trevi Therapeutics, Inc.宣布启动其在研疗法Haduvio（口服纳布啡缓释片）的2b期CORAL临床试验，该疗法旨在治疗特发性肺纤维化（IPF）、难治性慢性咳嗽（RCC）和结节性痒疹引起的慢性咳嗽患者。本试验将评估三种剂量Haduvio与安慰剂在约160名伴随慢性咳嗽的IPF患者的疗效。（资料来源：Trevi Therapeutics，新闻稿，2023）
加拿大临床阶段药物研发公司Algernon Pharmaceuticals Inc.宣布，已完成与美国私人药物研发公司Seyltx Inc.的协议，Seyltx Inc.将收购Algernon的NP-120（伊芬普罗地尔）研发专案。（资料来源：Algernon Pharmaceuticals Inc.，新闻稿，2024年）

慢性咳嗽市场报告涵盖范围及成果

这份题为《慢性咳嗽市场规模及预测（2021-2031）》的报告对市场进行了全面分析，涵盖以下领域：

涵盖范围内所有关键细分市场的全球、区域和国家层面的市场规模和预测
市场动态，例如驱动因素、限制因素和关键机会
未来主要趋势
详细的PEST/波特五力模型与SWOT分析
全球及区域市场分析，涵盖关键趋势、主要参与者、法规及最新发展
产业格局和竞争分析，包括市场集中度、热力图分析、主要参与者和最新发展动态
公司详细概况

In 2024, the chronic cough market was valued at approximately US$ 9.15 billion and is anticipated to grow to US$ 13.60 billion by 2031. The market is projected to experience a compound annual growth rate (CAGR) of 8.2% from 2031 to 2031. Increased awareness of respiratory issues, advancements in medical research and treatment options, along with ongoing drug development trends, are expected to be significant factors influencing the chronic cough market.

Chronic Cough Market Analysis

The global chronic cough market is largely propelled by the rising incidence of chronic lung infections, as a persistent cough is a common symptom, and the introduction of new treatments for chronic cough. The market's growth is also supported by a notable shift towards prioritizing respiratory health and wellness, alongside initiatives from both governmental and non-governmental organizations.

Chronic Cough Market Overview

A chronic cough is defined as one that persists for eight weeks or longer. It can be caused by infections, asthma, and gastroesophageal reflux disease (GERD). Symptoms associated with chronic cough include a sensation of mucus running down the throat (postnasal drip), headaches, frequent throat clearing, sore throat, hoarseness, shortness of breath, wheezing, a sour taste in the mouth, and heartburn. There has been a notable increase in investments in healthcare infrastructure, diagnostic services, and patient education programs aimed at enhancing the management and early detection of chronic cough.

Strategic Insights

Chronic Cough Market Drivers and Opportunities

Increasing Incidence of Chronic Cough to Boost Market Growth

Conditions such as infections, lung diseases, and bronchitis are likely contributors to chronic cough. The global rise in asthma cases, particularly among children and adults, is significant. A study titled "Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study" published in February 2024, reported that the prevalence of chronic cough varies between 2% and 18%. Factors commonly linked to chronic cough include smoking, asthma, chronic obstructive pulmonary disease (COPD), obesity, upper airway cough syndrome (UACS), and gastroesophageal reflux disease (GERD).

Growing Elderly Population Expected to Increase Demand for Chronic Cough Treatments

Older adults are more susceptible to chronic cough, with aging being a primary factor in reduced immunity. Age-related degeneration of organs and healthy tissues can lead to various health issues, with chronic cough being prevalent among the elderly. As individuals age, their respiratory systems deteriorate, increasing the likelihood of respiratory infections such as pneumonia and influenza.

The global aging population is on the rise, with both developed and developing nations experiencing lower mortality rates. Improvements in healthcare have enhanced public health, leading to increased life expectancy. According to the World Health Organization (WHO), by 2050, the global population aged 60 and older is expected to reach 2.1 billion, with the number of individuals aged 80 and above projected to triple from 2020 to 2050, reaching 426 million. Consequently, the growing elderly demographic is likely to drive demand for chronic cough treatments during the forecast period.

Chronic Cough Market Report Segmentation Analysis

The chronic cough market analysis is segmented by drug class, route of administration, and distribution channel.

By drug class, the market includes antihistamines, corticosteroids, decongestants, combination drugs, antibiotics, acid blockers, and other classes. The combination drug segment held the largest market share in 2023.
In terms of route of administration, the market is categorized into oral, injections, inhalation, and other methods. The oral segment accounted for the largest market share in 2023.
Regarding distribution channels, the market is divided into hospital pharmacies, online pharmacies, and retail pharmacies, with the hospital pharmacy segment leading the market in 2023.

Chronic Cough Market Share Analysis by Geography

The geographic analysis of the chronic cough market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has been the leading region in the chronic cough market. The increasing demand for over-the-counter (OTC) products is a significant factor expected to drive revenue growth in this region during the review period. Additionally, the rising number of chronic cough cases, a rapidly growing elderly population, increasing vehicle pollution, and heightened awareness of advanced treatment options are contributing to the demand for cough remedy products.

Chronic Cough Market Report Scope

Chronic Cough Market News and Recent Developments

The chronic cough market evaluation is based on qualitative and quantitative data obtained from primary and secondary research, including key corporate publications, association data, and databases. Recent developments in the chronic cough market include:

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the initiation of its Phase 2b CORAL clinical trial for its investigational therapy Haduvio (oral nalbuphine ER) aimed at patients with chronic cough due to idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, evaluating three doses against placebo in approximately 160 IPF patients with chronic cough. (Source: Trevi Therapeutics, Press Release, 2023)
Algernon Pharmaceuticals Inc., a Canadian clinical-stage pharmaceutical development company, announced the completion of its agreement with Seyltx Inc., a privately owned U.S.-based drug development company, for the acquisition of Algernon's NP-120 (Ifenprodil) research program. (Source: Algernon Pharmaceuticals Inc., Press Release, 2024)

Chronic Cough Market Report Coverage and Deliverables

The report titled "Chronic Cough Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

Market size and forecast at global, regional, and country levels for all key segments included in the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter's Five Forces and SWOT analysis
Global and regional market analysis covering key trends, major players, regulations, and recent developments
Industry landscape and competition analysis including market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Chronic Cough Market and By Drug Class
- 1.3.2 Chronic Cough Market and By Route of Administration
- 1.3.3 Chronic Cough Market and By Distribution Channel
- 1.3.4 Global Chronic Cough Market and By Geography

2. Chronic Cough Market and Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Chronic Cough Market and Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America andPEST Analysis
- 4.2.2 Europe and PESTAnalysis
- 4.2.3 Asia PacificandPEST Analysis
- 4.2.4 Middle East andAfrica and PEST Analysis
- 4.2.5 South and Central America
4.3 Expert Opinion

5. Chronic Cough Market and Key Market Dynamics

5.1 Market Drivers
- 5.1.1 RisingIncidences of Chronic Cough
- 5.1.2 Growing ProductDevelopments to Treat Chronic Cough
5.2 Market Restraints
- 5.2.1 Product Recalls
5.3 Market Opportunities
- 5.3.1 Aging Populationis Expected to Drive Demand for Chronic Cough Treatment
5.4 Future Trends
- 5.4.1 Continuous Trendof Drug Development
5.5 Impact Analysis

6. Chronic Cough Market and Global Analysis

6.1 Global Chronic Cough Market Revenue Forecast And Analysis
6.2 Global Chronic Cough Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Chronic Cough Market Analysis and By Drug Class

7.1 Overview
7.2 Chronic Cough Market Revenue Share, by Drug Class (2024 and 2031)
7.3 Antihistamines
- 7.3.1 Overview
- 7.3.2 Antihistamines:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.4 Corticosteroids
- 7.4.1 Overview
- 7.4.2 Corticosteroids:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.5 Decongestants
- 7.5.1 Overview
- 7.5.2 Decongestants:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.6 Combination Drug
- 7.6.1 Overview
- 7.6.2 CombinationDrug: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.7 Antibiotics
- 7.7.1 Overview
- 7.7.2 Antibiotics:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.8 Acid Blockers
- 7.8.1 Overview
- 7.8.2 Acid Blockers:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.9 Other Drug Class
- 7.9.1 Overview
- 7.9.2 Other DrugClass: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)

8. Chronic Cough Market and By Route of Administration

8.1 Overview
8.2 Chronic Cough Market, by Route of Administration, 2024 and 2031 (%)
8.3 Oral
- 8.3.1 Overview
- 8.3.2 Oral: ChronicCough Market and Revenue and Forecast to 2031 (US$ Million)
8.4 Injections
- 8.4.1 Overview
- 8.4.2 Injections:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
8.5 Inhalation
- 8.5.1 Overview
- 8.5.2 Inhalation:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
8.6 Other Route of Administration
- 8.6.1 Overview
- 8.6.2 Other Route of Administration: Chronic Cough Market and Revenue and Forecast to 2031 (US$Million)

9. Chronic Cough Market and By Distribution Channel

9.1 Overview
9.2 Chronic Cough Market, by Distribution Channel, 2024 and 2031 (%)
9.3 Hospital Pharmacy
- 9.3.1 Overview
- 9.3.2 HospitalPharmacy: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
9.4 Online Pharmacy
- 9.4.1 Overview
- 9.4.2 Online Pharmacy:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
9.5 Retail Pharmacy
- 9.5.1 Overview
- 9.5.2 Retail Pharmacy:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)

10. Chronic Cough Market and Geographic Analysis

10.1 North America: Chronic Cough Market
- 10.1.1 Overview
- 10.1.2 North America:Chronic Cough Market and Revenue and Forecast to 2031 (USD Million)
- 10.1.3 North America:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.1.4 North America:Chronic Cough Market, by Route of Administration , 2024 and 2031 (USD Million)
- 10.1.5 North America:Chronic Cough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.1.6 North America:Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.1.7 US: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.1.7.1 US: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.1.7.2 US: Chronic CoughMarket, by Drug Class, 2024 and 2031 (USD Million)
  - 10.1.7.3 US: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.1.7.4 US: Chronic Cough Market,by Distribution Channel , 2024 and 2031 (USD Million)
- 10.1.8 Canada: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.8.1 Canada: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.8.2 Canada: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.1.8.3 Canada: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.1.8.4 Canada: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.1.9 Mexico: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.9.1 Mexico: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.9.2 Mexico: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.1.9.3 Mexico: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.1.9.4 Mexico: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
10.2 Europe: Chronic Cough Market
- 10.2.1 Overview
- 10.2.2 Europe: ChronicCough Market - Revenue and Forecast to 2031 (USD Million)
- 10.2.3 Europe: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.2.4 Europe: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
- 10.2.5 Europe: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.6 Europe: ChronicCough Market, by Country, 2018 and 2031 (%)
- 10.2.7 Germany: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.7.1 Germany: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.7.2 Germany: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.2.7.3 Germany: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.7.4 Germany: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.8 UK: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.8.1 UK: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.8.2 UK: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.8.3 UK: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.9 France: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.9.1 France: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.9.2 France: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
  - 10.2.9.3 France: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.9.4 France: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.10 Spain: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.10.1 Spain: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.10.2 Spain: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.2.10.3 Spain: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.10.4 Spain: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.11 Italy: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.11.1 Italy: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.11.2 Italy: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.2.11.3 Italy: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.11.4 Italy: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
10.3 Asia Pacific: Chronic Cough Market
- 10.3.1 Overview
- 10.3.2 Asia Pacific:Chronic Cough Market - Revenue and Forecast to 2031 (USD Million)
- 10.3.3 Asia Pacific:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.3.4 Asia Pacific:Chronic Cough Market, by Route of Administration , 2024 and 2031 (USD Million)
- 10.3.5 Asia Pacific:Chronic Cough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.6 Asia Pacific:Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.3.7 China: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.7.1 China: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.3.7.2 China: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.7.3 China: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.7.4 China: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.8 Japan: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.8.1 Japan: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.3.8.2 Japan: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.8.3 Japan: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.8.4 Japan: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.9 India: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.9.1 India: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.3.9.2 India: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.9.3 India: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.9.4 India: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.10 South Korea: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.10.1 South Korea: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.10.2 South Korea: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.10.3 South Korea: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.10.4 South Korea: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.11 Australia: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.11.1 Australia: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.11.2 Australia: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.11.3 Australia: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.11.4 Australia: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
10.4 Middle East and Africa: Chronic Cough Market
- 10.4.1 Overview
- 10.4.2 Middle East andAfrica: Chronic Cough Market- Revenue and Forecast to 2031 (USD Million)
- 10.4.3 Middle East andAfrica: Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.4.4 Middle East andAfrica: Chronic Cough Market, by Route of Administration, 2024 and 2031 (USDMillion)
- 10.4.5 Middle East andAfrica: Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.4.6 Middle East andAfrica: Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.4.7 Saudi Arabia:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.7.1 Saudi Arabia:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.7.2 Saudi Arabia:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.4.7.3 Saudi Arabia:Chronic Cough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.4.7.4 Saudi Arabia:Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.4.8 UAE: Chronic CoughMarketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.8.1 UAE: Chronic CoughMarketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.8.2 UAE: Chronic CoughMarket, by Drug Class, 2024 and 2031 (USD Million)
  - 10.4.8.3 UAE: Chronic CoughMarket, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.4.8.4 UAE: Chronic Cough,Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.4.9 South Africa:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.9.1 South Africa:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.9.2 South Africa:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.4.9.3 South Africa:Chronic Cough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.4.9.4 South Africa:Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
10.5 South and Central America: Chronic Cough Market
- 10.5.1 Overview
- 10.5.2 South and CentralAmerica: Chronic Cough Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5.3 South and CentralAmerica: Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.5.4 South and CentralAmerica: Chronic Cough Market, by Route of Administration, 2024 and 2031 (USDMillion)
- 10.5.5 South and CentralAmerica: Chronic Cough Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.5.6 South and CentralAmerica: Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.5.7 Brazil: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.7.1 Brazil: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.7.2 Brazil: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.5.7.3 Brazil: ChronicCough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.5.7.4 Brazil: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.5.8 Argentina: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.8.1 Argentina: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.8.2 Argentina: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.5.8.3 Argentina: ChronicCough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.5.8.4 Argentina: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)

11. Impact of COVID-19 Pandemic on Global Chronic cough Market

11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment Of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Chronic Cough Market andIndustry Landscape

12.1 Overview
12.2 Growth Strategies in The Chronic Cough Market, 2016-2020
12.3 Inorganic Growth Strategies
- 12.3.1 Overview
12.4 Organic Growth Strategies
- 12.4.1 Overview

13. COMPANY PROFILES

13.1 Novartis AG
- 13.1.1 Key Facts
- 13.1.2 BusinessDescription
- 13.1.3 Products andServices
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.2.1 Key Facts
- 13.2.2 BusinessDescription
- 13.2.3 Products andServices
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 BusinessDescription
- 13.3.3 Products andServices
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 BusinessDescription
- 13.4.3 Products andServices
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 MYLAN N.V.
- 13.5.1 Key Facts
- 13.5.2 BusinessDescription
- 13.5.3 Products andServices
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Amneal Pharmaceuticals, Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products andServices
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Cipla Inc.
- 13.7.1 Key Facts
- 13.7.2 BusinessDescription
- 13.7.3 Products andServices
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Reckitt Benckiser Group plc.
- 13.8.1 Key Facts
- 13.8.2 BusinessDescription
- 13.8.3 Products andServices
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Sun Pharmaceutical Industries Ltd
- 13.9.1 Key Facts
- 13.9.2 BusinessDescription
- 13.9.3 Products andServices
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Aurobindo Pharma Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments